Diagnosis, biology and epidemiology of oligometastatic breast cancer

Autor: Eleonora De Maio, Gabrielle Selmes, Slimane Zerdoud, Eva Jouve, R. Aziza, Jean-Louis Lacaze, Ciprian Chira, F. Izar, Florence Dalenc, C. Massabeau, Mony Ung, Anne Pradines
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Oncology
Review
NA
not applicable
Circulating Tumor DNA
law.invention
Circulating tumor cell
Randomized controlled trial
law
Epidemiology
HER2
human epidermal growth factor receptor 2
ctDNA
circulating tumor DNA
RC254-282
Curative intent
Incidence (epidemiology)
Incidence
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
General Medicine
CTCs
circulating tumor cells
Neoplastic Cells
Circulating
Observational Studies as Topic
CT scan
Computed Tomography scan
18F-FDG-PET/CT
Positron Emission Tomography/Computed Tomography with 18fluorodeoxyglucose
Female
CTCs
Cohort study
medicine.medical_specialty
18F-FES
16α-[18F]-Fluoro- 17β-estradiol
Breast Neoplasms
MRI
Magnetic Resonance Imaging
OMD
oligometastatic disease
OS
overall survival
MBC
Metastatic Breast Cancer
Breast cancer
Internal medicine
RFS
relapse-free survival
Biomarkers
Tumor
medicine
Humans
OMBC
oligometastatic breast cancer
Oligometastatic breast cancer
Biology
business.industry
HR
hormone receptor
Definition
medicine.disease
WB-MRI
Whole-body MRI
MicroRNAs
NED
No Evidence of Disease
SBR grade
Scarf-Bloom-Richardson grade
SBRT
Stereotactic Body Radiotherapy
Surgery
Observational study
Observatory
business
Zdroj: Breast, Vol 59, Iss, Pp 144-156 (2021)
The Breast : Official Journal of the European Society of Mastology
ISSN: 1532-3080
Popis: Does oligometastatic breast cancer (OMBC) deserve a dedicated treatment? Although some authors recommend multidisciplinary management of OMBC with a curative intent, there is no evidence proving this strategy beneficial in the absence of a randomized trial. The existing literature sheds little light on OMBC. Incidence is unknown; data available are either obsolete or biased; there is no consensus on the definition of OMBC and metastatic sites, nor on necessary imaging techniques. However, certain proposals merit consideration. Knowledge of eventual specific OMBC biological characteristics is limited to circulating tumor cell (CTC) counts. Given the data available for other cancers, studies on microRNAs (miRNAs), circulating tumor DNA (ctDNA) and genomic alterations should be developed Finally, safe and effective therapies do exist, but results of randomized trials will not be available for many years. Prospective observational cohort studies need to be implemented.
Highlights • The incidence of oligometastatic breast cancer is unknown. • Only one publication provides information regarding the biology of these cancers. • Oligometastatic breast cancer and metastatic site definitions should be harmonized. • Prospective observational cohort studies are needed.
Databáze: OpenAIRE
Externí odkaz: